SynthesisEuropean journal of clinical pharmacology2017
Use of antidepressants and the risk of cardiovascular and cerebrovascular disease: a meta-analysis of observational studies.
Synthesis in European journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 5 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Inhibition of the serotonin transporter and risk of heart valve disease: A systematic review and meta-analysis.European journal of pharmacology · 2026Pooled it
- Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis.Annals of medicine · 2022Pooled it
- The Effects of Omega-3 Supplementation on Depression in Adults with Cardiometabolic Disease: A Systematic Review of Randomised Control Trials.Nutrients · 2022Pooled it
- Systematic review of Kaixinsan in treating depression: Efficacy and pharmacological mechanisms.Frontiers in behavioral neuroscience · 2022Pooled it
- Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review.JAMA psychiatry · 2019Pooled it
- Long-Term Cardiovascular Risks of Anticholinergic Versus Non-Anticholinergic Antidepressants: A Target Trial Emulation With Negative Control Correction.Pharmacoepidemiology and drug safety · 2026Article
- The Impact of Cognitive Impairment on Cardiovascular Disease.Journal of the American College of Cardiology · 2025Review
- Depression and Coronary Artery Disease-Where We Stand?Journal of clinical medicine · 2025Review
- Relationships between sarcopenia, depressive symptoms, and the risk of cardiovascular disease in Chinese population.The journal of nutrition, health & aging · 2024Article
- Association of post-stroke-initiated antidepressants with long-term outcomes in young adults with ischaemic stroke.Annals of medicine · 2022Article
- Article
- Deconstruction of Risk Prediction of Ischemic Cardiovascular and Cerebrovascular Diseases Based on Deep Learning.Contrast media & molecular imaging · 2022Article
- Article
- Assessment of psychiatric comorbidities and serotonergic or noradrenergic medication use on blood pressure using 24-hour ambulatory blood pressure monitoring.Journal of clinical hypertension (Greenwich, Conn.) · 2021Article
- Serotonin: a platelet hormone modulating cardiovascular disease.Journal of thrombosis and thrombolysis · 2021Review
- Repeated use of SSRIs potentially associated with an increase on serum CK and CK-MB in patients with major depressive disorder: a retrospective study.Scientific reports · 2021Article
- Risk of ischaemic stroke associated with antiepileptic drugs: a population-based case-control study in Catalonia.BMC neurology · 2021Article
- Depression and Endothelial Dysfunction in Psoriatic Arthritis: Is There Any Possible Relationship?Frontiers in medicine · 2021Article
- Antidepressant treatment in patients following acute coronary syndromes: a systematic review and Bayesian meta-analysis.ESC heart failure · 2020Article
- The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases.CNS drugs · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to systematically review studies quantifying the associations between antidepressants (ADs) use and the risk of cardiovascular (CV) outcomes.
methodsMedline was searched to October 2015 for full text articles in English. Prospective cohort and case-control studies were admitted if they investigated the relationship between current use of ADs as a whole, tricyclic antidepressants (TCAs) or selective serotonin reuptake inhibitors (SSRIs), and the onset CV events. Summary relative risks (RRs) with confidence intervals (CIs) were calculated using random-effects or fixed-effects models.
resultsA total of 99,367 incident cases of CV outcomes who met inclusion criteria were identified from 22 observational studies. Compared with no users of ADs, use of SSRIs was associated with an increased risk of cerebrovascular disease (RRs, 1.24; 95% CI, 1.15 to 1.34), while the use of TCA was associated with an increased risk of acute heart disease (RRs, 1.29; 95% CI, 1.09 to 1.54).
conclusionsThe results of this meta-analysis have to be taken with caution because even though an increased risk of cerebrovascular and acute heart disease was observed respectively in SSRIs and TCA users, the estimates are characterized by a high between study heterogeneity. Moreover, it was not possible to distinguish between the effects of ADs and depression itself. Further well-designed studies are required to confirm this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.